Physician profile
Atif Butt
NPI 1912359506
$3,556.75
in general payments reported to CMS, 2019-2025
24 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $201 · 2021: $263 · 2022: $636 · 2023: $416 · 2024: $817 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.61 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $461.43 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $373.20 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $343.74 | 2019-2024 | |
| Incyte Corporation | $265.18 | 2024-2025 | Jakafi, Niktimvo, Pemazyre |
| Pfizer INC. | $255.77 | 2019-2025 | |
| Genzyme Corporation | $233.04 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $229.43 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $206.57 | 2022-2024 | Teflaro, Dalvance |
| Janssen Scientific Affairs, LLC | $169.40 | 2022-2023 | Xarelto |
| Abbott Laboratories | $157.13 | 2019 | |
| Beigene USA, INC. | $138.40 | 2025 | Brukinsa |
| Tempus Ai, INC | $101.59 | 2024 | |
| Rigel Pharmaceuticals, INC. | $95.25 | 2024 | Tavalisse, Rezlidhia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $80.92 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $74.96 | 2025 | Darzalex, Tecvayli |
| Novocure INC. | $68.11 | 2025 | Optune Lua (Novottf-200t) |
| Array Biopharma INC | $38.50 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Allergan, INC. | $35.42 | 2020 | |
| Melinta Therapeutics, LLC | $30.58 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Bard Peripheral Vascular, INC. | $30.33 | 2021 | |
| Exelixis INC. | $30.10 | 2024 | Cabometyx |
| Cvrx, INC. | $28.83 | 2022 | |
| Amgen INC. | $26.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.